Tag Archives: cardiovascular

ESC statement on inflammation in atherosclerosis: more evidence needed before anti-inflammatory drugs can join statins as standard treatment

SOPHIA ANTIPOLIS, 15-May-2018 — /EuropaWire/ — A European Society of Cardiology (ESC) consensus statement on inflammation in atherosclerosis is published today in the European Journal of Preventive Cardiology. (1) Written by the ESC Working Group on Atherosclerosis and Vascular Biology, the document … Read the full press release

Luxembourg Institute of Health: researchers identified a circular RNA that can predict patient outcome after heart attack

Researchers from LIH’s Cardiovascular Research Unit and international collaborators published an article in the number one cardiology journal, Journal of the American College of Cardiology, in September 2016. They identified a circular RNA that can predict patient outcome after heart … Read the full press release

Loughborough University to receive part of UK’s health research investment on cardiovascular, respiratory and lifestyle conditions

Leicestershire, UK, 20-Sep-2016 — /EuropaWire/ — Loughborough University is to receive a slice of the UK’s largest ever investment into health research announced today by Health Secretary Jeremy Hunt. A regional consortium featuring Loughborough University and the University of Leicester, and … Read the full press release

AstraZeneca to present scientific abstracts from its cardiovascular and metabolic disease portfolio at European Society of Cardiology (ESC) Congress 2015 in London

LONDON, 31-8-2015 — /EuropaWire/ — Over 20 scientific abstracts from AstraZeneca’s cardiovascular and metabolic disease portfolio will be presented at this year’s European Society of Cardiology (ESC) Congress 2015 in London, including five oral presentations. Data being presented will focus … Read the full press release

SAVOR-TIMI-53 cardiovascular outcomes trial of ONGLYZA® results announced by AstraZeneca and Bristol-Myers Squibb

20-6-2013 — /europawire.eu/ — AstraZeneca and Bristol-Myers Squibb announced today top-line results of the Phase IV SAVOR-TIMI-53 (Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus) clinical trial of Onglyza ® (saxagliptin). In this study of adult patients with … Read the full press release